Filing Flows › Health Care › Senti Biosciences Holdings (SNTI)
Senti Biosciences Holdings (SNTI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Senti Biosciences Holdings (SNTI) Q2 2026 earnings results →
Senti Biosciences Holdings made $17K in Q2 2026. Operating margin n/m, net loss $12.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $17K in Q2 2026, up 6% from the previous quarter.
Operating costs exceeded revenue by $14.5M, an operating margin of -85229.4%. The quarter ended with a net loss of $12.8M, wider than the previous quarter's $4.2M loss.
Operating cash flow was −$14.2M. Non-cash charges added back $667K of depreciation and $1.0M of share-based compensation. Working capital and other items used $3.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $17K | — | n/m | −$12.8M | −$14.2M |
| Q1 2026 | 10-Q | May 14, 2026 | $16K | — | n/m | −$4.2M | −$7.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Senti Biosciences Holdings
Unless the context otherwise requires, for purposes of this section, the terms “we,” “us,” “our,” “our Company,” “the Company” or “Senti” refer to Senti Biosciences, Inc. and its subsidiaries. We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits.
In its own words, from its 10-K, filed Mar 27, 2026.
Senti Biosciences Holdings against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SNTI Senti Biosciences Holdings | Q2 2026 | $17K | — | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Senti Biosciences Holdings 10-Q on SEC EDGAR · CIK 1854270 · Biological Products, (No Diagnostic Substances)
13F: who owns SNTI and who is buying
More on SNTI
- How Senti Biosciences Holdings makes money: revenue by segment
- Senti Biosciences Holdings stock forecast, price target and fair value
- Who owns Senti Biosciences Holdings stock: holders, funds and Congress trades
- Is Senti Biosciences Holdings a takeover target? LBO and rumors
- Senti Biosciences Holdings recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results